Idera Pharmaceuticals (IDRA)
Idera Pharmaceuticals News
Idera Pharmaceuticals, Inc. (IDRA) Posts Narrower than Expected Q1 Loss
Street Insider about 21 days agoIdera Pharmaceuticals Reports First Quarter 2012 Financial Results
Business Wire about 21 days agoIdera Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.
IDERA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
about 21 days agoIdera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis
Business Wire about 23 days agoIdera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus and psoriasis.
Idera Pharmaceuticals Announces Top-line Results from a Phase 2 Clinical Trial of IMO-2055; Did Not Meet Primary Endpoints
Benzinga about 27 days agoIdera (IDRA) Reports IMO-2055 Missed Top-Line Endpoint in Phase 2
Street Insider about 27 days agoIdera Pharmaceuticals Announces Top-line Results from a Phase 2 Clinical Trial of IMO-2055 in Treatment of Patients with Advanced Head and Neck Cancer
Business Wire about 27 days agoIdera Pharmaceuticals, Inc. today announced top-line results of a randomized, controlled Phase 2 clinical trial of IMO-2055, the Company’s investigational oncology product candidate targeting Toll-like Receptor 9 in combination with Erbitux® for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in patients who previously progressed on chemotherapy.
Idera Pharmaceuticals Announces Presentation of Preclinical Data of IMO-8400 in Both Lupus and Psoriasis Models
Business Wire about 29 days agoIdera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor inhibitor, IMO-8400, in models of systemic lupus erythematosus and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.
Idera (IDRA) Initiates TLR Inhibitor IMO-3100 Phase 2
Street Insider about 43 days agoIdera Pharmaceuticals Announces Initiation of Treatment in Phase 2 Clinical Trial of IMO-3100 for Psoriasis
Benzinga about 43 days agoIDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
about 47 days agoAmgen Psoriasis Candidate Impresses
about 55 days agoZacks #5 Rank Additions for Wednesday - Tale of the Tape
Zacks about 56 days agoHere are 5 stocks added to the Zacks #5 Rank ("strong sell") List for Wednesday
Zacks #5 Rank Additions for Wednesday
about 56 days agoYou may also be interested in these IDRA related companies
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IDRA | 1.00 | -0.02 | -1.96% | 27.64M |
| IDN | 1.64 | -0.09 | -5.07% | 47.44M |
| IDIX | 9.41 | -0.27 | -2.79% | 1.041B |
| IDI | 1.85 | -0.03 | -1.60% | 38.59M |
| IDCC | 25.28 | +0.14 | +0.56% | 1.134B |
| IDA | 39.30 | +0.17 | +0.43% | 1.955B |
| ICUI | 52.22 | +0.21 | +0.40% | 722.94M |
| ICS | 15.36 | +0.07 | +0.46% | |
| ICON | 15.86 | +0.38 | +2.45% | 1.123B |
| ICLR | 21.90 | -0.03 | -0.14% | 1.319B |
